성능/효과

• 01). This clinical study demonstrated that exenatide therapy significantly improved glycemic control in patients with type 2 diabetes and was associated with significant sustained weight loss when added to the commonly used combination therapy of metformin and a sulfonylurea. This therapy may offer another potential treatment option when two-drug therapy fails to maintain adequate glycemic control.
• 001). This clinical trial demonstrated that exenatide 10 μg twice daily therapy in addition to metformin improved overall hyperglycemia in a group of type 2 diabetes with less-than-optimal glycemic control, with about 40 % of patients able to reach an HbA1C treatment goal of ≤7%. It was also noteworthy that exenatide treatment elicited dose-dependent reduction in body weight.
• 05). This clinical trial demonstrated that long-term use of exenatide at fixed doses of 5 and 10 mg twice daily appears to have potential for the treatment of patients with type 2 diabetes not adequately controlled with sulfonylurea agents, with 41.3% able to reach and maintain an HbA1C ≤7% in the 10 pg twice daily dose at the end of 30 weeks.